Alnylam Pharma (ALNY) Received its Third Buy in a Row
After Cantor Fitzgerald and Piper Jaffray gave Alnylam Pharma (NASDAQ: ALNY) a Buy rating last month, the company received another Buy, this time from BMO Capital. Analyst Do Kim maintained a Buy rating on Alnylam Pharma today and set a price target of $126. The company’s shares opened today at $91.23.
According to TipRanks.com, Kim is a 5-star analyst with an average return of 18.3% and a 59.4% success rate. Kim covers the Healthcare sector, focusing on stocks such as Ionis Pharmaceuticals Inc, Vertex Pharmaceuticals, and Akcea Therapeutics Inc.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Alnylam Pharma with a $123.45 average price target, representing a 35.3% upside. In a report issued on April 10, Stifel Nicolaus also maintained a Buy rating on the stock with a $110 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $124.22 and a one-year low of $60.27. Currently, Alnylam Pharma has an average volume of 803.3K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Alnylam Pharmaceuticals, Inc. operates as biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics. It is the translation of RNAi as a new class of innovative medicines with a core focus on RNAi therapeutics for the treatment of genetically defined diseases.